Medicine guide

Tranexamic Acid

100 mg/mL · Injection, Solution

Prescription only
Antifibrinolytic Agent

Active substance: Tranexamic Acid
Used in: Blood, clotting and anaemia
Made by: Sagent Pharmaceuticals
Source: Official label

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

At a glance

Quoted from the official label · 2025-09-19

What it is

Antifibrinolytic Agent

Used for

Tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.

The label’s usual adult dose

Administer 10 mg/kg actual body weight of tranexamic acid injection intravenously with replacement therapy.

Full directions ↓

Do not take it if

Tranexamic acid injection is contraindicated: In patients with subarachnoid hemorrhage.

All warnings ↓

Good to know

Prescription only
FDA enforcement reports list no ongoing recall, and none from the last two years, for this product code · checked 2026-10-02

41other products contain Tranexamic Acid — compare makers, forms and strengths

Every line above is selected, not written, from the official label. Nothing is reworded. DailyMed

What it is for

Tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.
Tranexamic acid is an antifibrinolytic indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.
( 1 )

From the official label · 2025-09-19 · DailyMed

How it works

From this product’s own US prescribing label.

Tranexamic acid is a synthetic lysine amino acid derivative, which diminishes the dissolution of hemostatic fibrin by plasmin.
In the presence of tranexamic acid, the lysine receptor binding sites of plasmin for fibrin are occupied, preventing binding to fibrin monomers, thus preserving and stabilizing fibrin's matrix structure.

Half-life2 h

Mostly cleared after≈ 10 hfive half-lives — our arithmetic

How it leaves the body

Overall renal clearance is equal to overall plasma clearance (110 to 116 mL/min), and more than 95% of the dose is excreted in the urine as unchanged drug.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-09-19

Do not take it if

Tranexamic acid injection is contraindicated: In patients with subarachnoid hemorrhage.
Anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid injection in such patients.
In patients with active intravascular clotting [see Warnings and Precautions ( 5.1 )] .
In patients with hypersensitivity to tranexamic acid or any of the ingredients [see Warnings and Precautions ( 5.4 )] .
In patients with subarachnoid hemorrhage, due to risk of cerebral edema and cerebral infarction.
( 4 ) In patients with active intravascular clotting.
( 4 ) In patients with severe hypersensitivity reactions to tranexamic acid or any of the ingredients.
( 4 )

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

Before Extraction:
Administer 10 mg/kg actual body weight of tranexamic acid injection intravenously with replacement therapy.
( 2.1 ) After Extraction:
Administer 10 mg/kg actual body weight 3 to 4 times daily for 2 to 8 days.
Infuse no more than 1 mL/minute to avoid hypotension.
( 2.1 ) Reduce the dosage for patients with renal impairment.
( 2.2 , 8.6 )
2.1 Recommended Dosage The recommended dose of tranexamic acid injection is 10 mg/kg actual body weight intravenously administered as a single-dose, immediately before tooth extractions.
Infuse no more than 1 mL/minute to
avoid hypotension [see Warnings and Precautions ( 5.1 )].
Following tooth extraction, tranexamic acid injection may be administered for 2 to 8 days at a dose of 10 mg/kg actual body weight 3 to 4 times daily, intravenously.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
For intravenous infusion, tranexamic acid injection may be mixed with most solutions for infusion such as electrolyte solutions, carbohydrate solutions, amino acid solutions, and Dextran solutions.
Heparin may be added to tranexamic acid injection.
Tranexamic acid injection should NOT be mixed with blood.
The drug is a synthetic amino acid and should NOT be mixed with solutions containing penicillin.
Discard any unused portion.
The diluted mixture may be stored for up to 4 hours at room temperature prior to patient administration.
2.2 Recommended Dosage for Patients with Varying Degrees of Renal Impairment * For patients with moderate to severe impaired renal function, the following dosages are recommended:
Table 1:
Recommended Dosage in Patients with Varying Degrees of Renal Impairment * Dose reduction is recommended for all doses, both before and after tooth extraction.
Serum Creatinine (mg/dL) Tranexamic Acid Injection Intravenous Dosage 1.36 to 2.83 (120 to 250 micromol/L) 10 mg/kg twice daily 2.83 to 5.66 (250 to 500 micromol/L) 10 mg/kg daily >5.66 (>500 micromol/L) 10 mg/kg every 48 hours or 5 mg/kg every 24 hours

Quoted from the official label, section “Dosage & Administration”.

Other warnings

Risk of Thrombosis with Concomitant Use of Factor IX: Avoid concomitant use.
( 5.1 ) Risk of Medication Errors Due to Incorrect Route of Administration:
FOR INTRAVENOUS USE ONLY.
( 5.2 ) Seizures: Inadvertent injection into neuraxial system may result in seizures.
( 5.3 ) Hypersensitivity Reactions:
In case of severe reaction, discontinue use and seek immediate medical attention.
( 5.4 ) Visual Disturbances: Visual or ocular adverse effects may occur.
Discontinue use if visual or ocular symptoms occur.
( 5.5 ) Dizziness: Advise patients not to drive if dizziness occurs.
( 5.6 )
5.1 Thromboembolic Risk Tranexamic acid is contraindicated in patients with active intravascular clotting.
Tranexamic acid is an antifibrinolytic and may increase the risk of thromboembolic events.
Venous and arterial thrombosis or thromboembolism has been reported in patients treated with tranexamic acid.
Avoid concomitant use of tranexamic acid and medical products that are pro-thrombotic, as the risk of thrombosis may be increased.
These medications include but are not limited to, Factor IX Complex concentrates, Anti-inhibitor Coagulant concentrates, and hormonal contraceptives [see Drug Interactions ( 7.1 ), Use in Specific Populations ( 8.3 )] .
5.2 Risk of Medication Errors Due to Incorrect Route of Administration Tranexamic acid injection is for intravenous use only.
Serious adverse reactions including seizures and cardiac arrythmias have occurred when tranexamic acid injection was inadvertently administered intrathecally instead of intravenously.
Confirm the correct route of administration for tranexamic acid injection and
avoid confusion with other injectable solutions that might be administered at the same time as tranexamic acid injection.
Syringes containing tranexamic acid injection should be clearly labeled with the intravenous route of administration.
5.3 Seizures Tranexamic acid may cause seizures, including focal and generalized seizures.
The most common setting for tranexamic acid-induced seizures has been during cardiovascular surgery (a setting in which tranexamic acid is not FDA-approved and which uses doses of up to 10-fold higher than the recommended human dose and in patients inadvertently given tranexamic acid into the neuraxial system).
Tranexamic acid is not approved and not recommended for neuraxial administration.
Consider dose reduction during surgery and dose adjustments for patients with clinical conditions such as renal dysfunction.
Closely monitor the patient during surgery.
Consider electroencephalogram (EEG) monitoring for patients with history of seizures or who experience myoclonic movements, twitching, or show evidence of focal seizures.
Discontinue tranexamic acid if seizures occur.
5.4 Hypersensitivity Reactions Cases of hypersensitivity reactions, including anaphylactic reactions, have occurred with use of intravenous tranexamic acid.
Discontinue treatment with tranexamic acid if serious reaction occurs, provide appropriate medical management, and do not restart treatment.
Tranexamic acid is contraindicated in patients with a history of hypersensitivity to tranexamic acid.
5.5 Visual Disturbances Although not seen in humans, focal areas of retinal degeneration have been observed in cats and dogs following oral or intravenous tranexamic acid at doses between 250 to 1600 mg/kg/day (1.6 to 22 times the recommended usual human dose based on body surface area) from 6 days to 1 year.
No retinal changes have been observed in eye examinations of patients treated with tranexamic acid for up to 8 years.
Patients expected to be treated for greater than 3 months may consider ophthalmic monitoring including visual acuity and optical coherence tomography at regular intervals.
Discontinue tranexamic acid if changes in ophthalmological examination occurs.
5.6 Dizziness Tranexamic acid may cause dizziness.
Concomitant use of other drugs that may also cause dizziness may worsen this effect.
Advise patients to
avoid driving or using machines until they know how tranexamic acid affects them.

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

Risk Summary Available data from published studies, case series and case reports with tranexamic acid use in pregnant women in the second and third trimester and at the time of delivery have not clarified whether there is a drug-associated risk of miscarriage or adverse maternal or fetal outcomes.
There are 2 (0.02%) infant cases with structural abnormalities that resulted in death when tranexamic acid was used during conception or the first trimester of pregnancy; however, due to other confounding factors the risk of major birth defects with use of tranexamic acid during pregnancy is not clear.
Tranexamic acid is known to pass the placenta and appears in cord blood at concentrations approximately equal to maternal concentration (see Data ) .
Reproduction studies performed in mice, rats, and rabbits have not revealed any adverse effects on the fetus due to tranexamic acid administered during organogenesis.
Doses examined were multiples of up to 3 times (mouse), 6 times (rat), and 3 times (rabbit) the maximum human dose based on body surface area in the mouse, rat, and rabbit, respectively (see Data ) .
The estimated background risk for major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
It is not known whether tranexamic acid use in pregnant women may cause a drug-associated risk of miscarriage or adverse maternal or fetal outcomes.
For decisions regarding the use of tranexamic acid during pregnancy, the potential risk of tranexamic acid administration on the fetus should always be considered along with the mother's clinical need for tranexamic acid; an accurate risk-benefit evaluation should drive the treating physician's decision.
Data Human Data Tranexamic acid passes through the placenta.
The concentration in cord blood after an intravenous injection of 10 mg/kg to pregnant women is about 30 mg/L, as high as in the maternal blood.
There were 13 clinical studies that described fetal and/or neonatal functional issues such as low Apgar score, neonatal sepsis, cephalohematoma and 9 clinical studies that discussed alterations to growth including low birth weight and preterm birth at 22 to 36 weeks of gestation in fetuses and infants exposed to tranexamic acid in-utero.
Animal Data In embryo-fetal development studies, tranexamic acid was administered to pregnant mice from Gestation day (GD) 6 through GD 12 and rats from GD 9 through GD 14 at daily doses of 0.3 or 1.5 g/kg.
There was no evidence of adverse developmental outcomes in mice and rats at multiple of 3 and 6 times the maximum recommended human dose based on body surface area in the mouse and rat, respectively.
In rabbits, tranexamic acid was administered intravenously at doses of 50, 100, or 200 mg/kg/day or orally at doses of 100, 200, or 400 mg/kg/day from GD 6 through GD 18.
There was no evidence of adverse developmental outcomes at dose multiples of 2 or 3 times, respectively, the maximum recommended human dose based on body surface area.
Intravenous doses of 200 mg/kg/day showed slightly retarded weight gain in pregnant rabbits.
IN SPECIFIC POPULATIONS
8.1 Pregnancy Risk Summary Available data from published studies, case series and case reports with tranexamic acid use in pregnant women in the second and third trimester and at the time of delivery have not clarified whether there is a drug-associated risk of miscarriage or adverse maternal or fetal outcomes.
There are 2 (0.02%) infant cases with structural abnormalities that resulted in death when tranexamic acid was used during conception or the first trimester of pregnancy; however, due to other confounding factors the risk of major birth defects with use of tranexamic acid during pregnancy is not clear.
Tranexamic acid is known to pass the placenta and appears in cord blood at concentrations approximately equal to maternal concentration (see Data ) .
Reproduction studies performed in mice, rats, and rabbits have not revealed any adverse effects on the fetus due to tranexamic acid administered during organogenesis.
Doses examined were multiples of up to 3 times (mouse), 6 times (rat), and 3 times (rabbit) the maximum human dose based on body surface area in the mouse, rat, and rabbit, respectively (see Data ) .
The estimated background risk for major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
It is not known whether tranexamic acid use in pregnant women may cause a drug-associated risk of miscarriage or adverse maternal or fetal outcomes.
For decisions regarding the use of tranexamic acid during pregnancy, the potential risk of tranexamic acid administration on the fetus should always be considered along with the mother's clinical need for tranexamic acid; an accurate risk-benefit evaluation should drive the treating physician's decision.
Data Human Data Tranexamic acid passes through the placenta.
The concentration in cord blood after an intravenous injection of 10 mg/kg to pregnant women is about 30 mg/L, as high as in the maternal blood.
There were 13 clinical studies that described fetal and/or neonatal functional issues such as low Apgar score, neonatal sepsis, cephalohematoma and 9 clinical studies that discussed alterations to growth including low birth weight and preterm birth at 22 to 36 weeks of gestation in fetuses and infants exposed to tranexamic acid in-utero.
Animal Data In embryo-fetal development studies, tranexamic acid was administered to pregnant mice from Gestation day (GD) 6 through GD 12 and rats from GD 9 through GD 14 at daily doses of 0.3 or 1.5 g/kg.
There was no evidence of adverse developmental outcomes in mice and rats at multiple of 3 and 6 times the maximum recommended human dose based on body surface area in the mouse and rat, respectively.
In rabbits, tranexamic acid was administered intravenously at doses of 50, 100, or 200 mg/kg/day or orally at doses of 100, 200, or 400 mg/kg/day from GD 6 through GD 18.
There was no evidence of adverse developmental outcomes at dose multiples of 2 or 3 times, respectively, the maximum recommended human dose based on body surface area.
Intravenous doses of 200 mg/kg/day showed slightly retarded weight gain in pregnant rabbits.
8.2 Lactation Risk Summary Published literature reports the presence of tranexamic acid in human milk.
There are no data on the effects of tranexamic acid on the breastfed child or the effects on milk production.
The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for tranexamic acid and any potential adverse effects on the breastfed child from tranexamic acid or from the underlying maternal condition.
8.3 Females and Males of Reproductive Potential Contraception Concomitant use of tranexamic acid, which is an antifibrinolytic, with hormonal contraceptives may increase the risk for thromboembolic adverse reactions.
Advise patients to use an effective alternative (nonhormonal) contraceptive method [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 )] .
8.4 Pediatric Use There are limited data concerning the use of tranexamic acid in pediatric patients with hemophilia who are undergoing tooth extraction.
The limited data suggest that there are no significant pharmacokinetic differences between
adults and pediatric patients.
8.5 Geriatric Use Clinical studies of tranexamic acid did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration ( 2.2 ), Clinical Pharmacology ( 12.3 )] .
8.6 Renal Impairment Reduce the dosage of tranexamic acid in patients with renal impairment, based on the patient's serum creatinine [see Dosage and Administration ( 2.2 ), Clinical Pharmacology ( 12.3 )] .

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

Prothrombotic Medical Products:
Avoid concomitant use, can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid.
( 5.1 , 7.1 , 8.3 )
Prothrombotic Medical Products
Avoid concomitant use of tranexamic acid with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions ( 5.1 ), Use in Specific Populations ( 8.3 )] .

Quoted from the official label, section “Drug Interactions”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

Cases of overdosage of tranexamic acid have been reported.
Based on these reports, symptoms of overdosage may be gastrointestinal, e.g., nausea, vomiting, diarrhea; hypotensive, e.g., orthostatic symptoms; thromboembolic, e.g., arterial, venous, embolic; neurologic, e.g., visual impairment, convulsions, headache, mental status changes; myoclonus; and rash.

Quoted from the official label, section “Overdosage”.

Use in children

There are limited data concerning the use of tranexamic acid in pediatric patients with hemophilia who are undergoing tooth extraction. The limited data suggest that there are no significant pharmacokinetic differences between
adults and pediatric patients.

Quoted from the official label, section “Pediatric Use”.

Use in older people

Clinical studies of tranexamic acid did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration ( 2.2 ), Clinical Pharmacology ( 12.3 )] .

Quoted from the official label, section “Geriatric Use”.

Side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:
Thromboembolic Risk [see Warnings and Precautions ( 5.1 )] Seizures [see Warnings and Precautions ( 5.3 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.4 )] Visual Disturbances [see Warnings and Precautions ( 5.5 )] Dizziness [see Warnings and Precautions ( 5.6 )] Most common adverse reactions are nausea, vomiting, diarrhea, allergic dermatitis, giddiness, hypotension, and thromboembolic events.
( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of tranexamic acid.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Gastrointestinal disturbances (nausea, vomiting, diarrhea) may occur and may resolve with dose-reduction.
Allergic dermatitis and giddiness have been reported.
Hypotension has been reported when intravenous injection is too rapid.
Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, cerebral thrombosis, acute renal cortical necrosis, and central retinal artery, vein obstruction and cases associated with concomitant use of combination hormonal contraceptives) have been rarely reported in patients receiving tranexamic acid for indications other than hemorrhage prevention in patients with hemophilia.
Convulsion, cromatopsia, and visual impairment have also been reported.
Anaphylaxis or anaphylactoid reactions have been reported that are suggestive of a causal relationship.

Quoted from the official label, section “Adverse Reactions”.

What to discuss with your doctor

Thromboembolic Risk Inform patients that tranexamic acid injection may increase the risk of venous and arterial thrombosis or thromboembolism and to contact their healthcare provider for any signs or symptoms suggestive of thromboembolism.
Advise patients using hormonal contraception that combined use with tranexamic acid injection may increase the risk for thromboembolic adverse reactions and to use effective alternative (nonhormonal) contraception during therapy with tranexamic acid injection [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 ), Use in Specific Populations ( 8.3 )] .
Seizures Inform patients that tranexamic acid injection may cause seizures and to contact their healthcare provider for any signs or symptoms suggestive of seizures [see Warnings and Precautions ( 5.3 )] .
Hypersensitivity Reactions Inform patients that tranexamic acid injection may cause hypersensitivity reactions and to contact their healthcare provider for any signs or symptoms of hypersensitivity reactions [see Warnings and Precautions ( 5.4 )] .
Visual Disturbances Inform patients that tranexamic acid injection can cause visual disturbance and that they should report any eye symptoms or change in their vision to their healthcare provider and to follow-up with an ophthalmologist for a complete ophthalmologic evaluation, including dilated retinal examination of the retina [see Warnings and Precautions ( 5.5 )] .
Risk of Driving and Operating Machinery Inform patients that tranexamic acid injection may cause dizziness, and that the patient should be cautioned about driving, operating machinery, or performing hazardous tasks while taking tranexamic acid injection [see Warnings and Precautions ( 5.6 )] .
PREMIER ProRx ® Mfd. for SAGENT Pharmaceuticals Schaumburg, IL 60173 (USA) Made in India ©2025 Sagent Pharmaceuticals PREMIERProRx ® is a registered trademark of Premier Healthcare Alliance, L.P., used under license.
March 2025

Quoted from the official label, section “Patient Counseling Information”.

Strengths and forms

FORMS AND STRENGTHS Injection:
1,000 mg tranexamic acid, USP (100 mg per mL) clear and colorless solution in 10 mL single-dose vials. Injection:
1,000 mg tranexamic acid (100 mg per mL) in 10 mL single-dose vials. ( 3 )

Quoted from the official label, section “Dosage Forms & Strengths”.

What it looks like and how it is packed

Tranexamic Acid Injection, USP is a clear, colorless solution supplied as follows:
NDC Tranexamic Acid Injection, USP (100 mg per mL) Package Factor 25021-415-66 1,000 mg per 10 mL Single-Dose Vial 10 vials per carton Storage Conditions
Store at 20º to 25°C (68º to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.] Discard unused portion.
Sterile, Nonpyrogenic, Preservative-free.
The container closure is not made with natural rubber latex.

Quoted from the official label, section “How Supplied”.

How to store it

Conditions
Store at 20º to 25°C (68º to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.] Discard unused portion.
Sterile, Nonpyrogenic, Preservative-free.
The container closure is not made with natural rubber latex.

Quoted from the official label, section “Storage and Handling”.

What is in it

Tranexamic acid is trans-4-(aminomethyl)cyclohexanecarboxylic acid, an antifibrinolytic agent.
Tranexamic acid, USP is a white crystalline powder.
The structural formula is Empirical Formula: C 8 H 15 NO 2 Molecular Weight:
157.2 Each mL of the sterile solution for intravenous injection contains 100 mg tranexamic acid, USP and Water for Injection to 1 mL.
The aqueous solution for injection has a pH of 6.5 to 8.0.
Structural Formula

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

The stored label for this product has no list of inactive ingredients. The list on the pack is the one to check.

Quoted from the FDA label. A label that does not name an ingredient is not a guarantee that the product is free of it, and formulations change. With an allergy, check the pack and ask a pharmacist.

Every version of this medicine (19)

The same active substance, strength and kind of form, from every company that sells it — with what each label lists.

Showing 19 of 19

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

CanadaNo exact match for this strength and form

Every strength and form (21)

Details

Made by	Sagent Pharmaceuticals
Active substance	Tranexamic Acid
Used in	Blood, clotting and anaemia
Strength	100 mg/mL
Form	Injection, Solution
Route	Intravenous
Packs	10 VIAL in 1 CARTON / 10 mL in 1 VIAL
NDC	25021-415

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

35 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Injection, Solution15 products
- 1 g/10mL2
  1 g/10mL · 2 companies
  - Emcure Pharmaceuticals Limited
  - Heritage Pharmaceuticals Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc.
- 10 mg/mL2
  10 mg/mL · 2 companies
  - Nexus Pharmaceuticals LLC
  - Sagent Pharmaceuticals
- 100 mg/mL11
  100 mg/mL · 11 companies
  +3 more
Tablet11 products
- 650 mg11
  650 mg · 11 companies
  +3 more
Injection7 products
- 100 mg/mL7
  100 mg/mL · 7 companies
Tablet, Film Coated2 products
- 650 mg2
  650 mg · 2 companies
  - Actavis Pharma, Inc.
  - Bryant Ranch Prepack

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

Cyklokapron100 mg/mLPrescription onlyInjection, Solution Pfizer Laboratories Div Pfizer Inc · Tranexamic Acid Tranexamic Acid650 mgPrescription onlyTablet, Film Coated Actavis Pharma, Inc. · Tranexamic Acid Tranexamic Acid1 g/10mLPrescription onlyInjection, Solution Emcure Pharmaceuticals Limited · Tranexamic Acid Tranexamic Acid10 mg/mLPrescription onlyInjection, Solution Nexus Pharmaceuticals LLC · Tranexamic Acid Tranexamic Acid1 g/10mLPrescription onlyInjection, Solution Heritage Pharmaceuticals Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. · Tranexamic Acid Tranexamic Acid100 mg/mLPrescription onlyInjection Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. · Tranexamic Acid

See every product with Tranexamic Acid